BR112015008076A2 - composição farmacêutica, e, método de preparar uma composição - Google Patents

composição farmacêutica, e, método de preparar uma composição

Info

Publication number
BR112015008076A2
BR112015008076A2 BR112015008076A BR112015008076A BR112015008076A2 BR 112015008076 A2 BR112015008076 A2 BR 112015008076A2 BR 112015008076 A BR112015008076 A BR 112015008076A BR 112015008076 A BR112015008076 A BR 112015008076A BR 112015008076 A2 BR112015008076 A2 BR 112015008076A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
preparing
binder
filler
hygroscopic
Prior art date
Application number
BR112015008076A
Other languages
English (en)
Inventor
Sedmak Gregor
Original Assignee
Zentiva Ks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva Ks filed Critical Zentiva Ks
Publication of BR112015008076A2 publication Critical patent/BR112015008076A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

1 / 1 resumo “composiã‡ãƒo farmacãšutica, e, mã‰todo de preparar uma composiã‡ãƒo” a presente soluã§ã£o prov㪠uma formulaã§ã£o farmacãªutica oral, sã³lida contendo ticagrelor, tendo o nome quã­mico (1s,2s,3r,5s)-3-[7- [[(1r,2s)-2-(3,4-difluorofenil)ciclopropil]amino]-5-(propiltio)-3h-1,2,3-triazol[4,5- d]pirimidin-3-il]-5-(2-hidroxietoxi)-1,2-ciclopentanodiol, compreendendo pelo menos uma carga nã£o higroscã³pica e/ou pelo menos um aglutinante nã£o higroscã³pico, em que nem a carga, nem o aglutinante tem qualquer efeito desintegrante. a preparaã§ã£o da formulaã§ã£o ã© possã­vel por granulaã§ã£o a ãºmido ou granulaã§ã£o a seco ou compressã£o direta.
BR112015008076A 2012-10-16 2013-10-15 composição farmacêutica, e, método de preparar uma composição BR112015008076A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2012-705A CZ2012705A3 (cs) 2012-10-16 2012-10-16 Pevná orální farmaceutická formulace obsahující ticagrelor
PCT/CZ2013/000130 WO2014059955A1 (en) 2012-10-16 2013-10-15 A solid oral pharmaceutical formulation containing ticagrelor

Publications (1)

Publication Number Publication Date
BR112015008076A2 true BR112015008076A2 (pt) 2017-07-04

Family

ID=49619770

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008076A BR112015008076A2 (pt) 2012-10-16 2013-10-15 composição farmacêutica, e, método de preparar uma composição

Country Status (13)

Country Link
EP (1) EP2908802A1 (pt)
JP (1) JP6301934B2 (pt)
KR (1) KR20150067153A (pt)
CN (1) CN104661649A (pt)
BR (1) BR112015008076A2 (pt)
CZ (1) CZ2012705A3 (pt)
EA (1) EA201590745A1 (pt)
HK (1) HK1205456A1 (pt)
IL (1) IL238036B (pt)
MX (1) MX2015003866A (pt)
UA (1) UA116784C2 (pt)
WO (1) WO2014059955A1 (pt)
ZA (1) ZA201501954B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160012706A (ko) * 2014-07-25 2016-02-03 동아에스티 주식회사 서방성 제제
CN106074357B (zh) * 2015-04-29 2021-07-02 江苏恒瑞医药股份有限公司 一种替格瑞洛或其可药用盐的制剂
CN105193759B (zh) * 2015-09-18 2018-07-03 乐普药业股份有限公司 一种替格瑞洛片及其制备方法
CN106667926B (zh) * 2015-11-09 2020-01-17 石药集团中奇制药技术（石家庄）有限公司 一种法匹拉韦片剂及其制备方法
TR201601835A2 (tr) * 2016-02-12 2017-08-21 Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇kagrelor i̇çeren formülasyonlar i̇çi̇n üreti̇m yöntemi̇
WO2017182589A1 (en) * 2016-04-21 2017-10-26 Astrazeneca Ab Orally disintegrating tablets
TR201617983A2 (tr) * 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇cagrelorun kati oral farmasöti̇k bi̇leşi̇mleri̇
KR102610876B1 (ko) * 2018-03-05 2023-12-06 주식회사 파마코스텍 티카그렐러 푸마르산 i형 결정 및 그 제조방법
WO2019170244A1 (en) 2018-03-08 2019-09-12 Pharmaceutical Oriented Services Ltd. Ticagrelor—containing tablet formulation
WO2020021110A1 (en) 2018-07-27 2020-01-30 Krka, D.D., Novo Mesto Pharmaceutical composition of ticagrelor
CN111450067A (zh) * 2019-01-18 2020-07-28 北京万全德众医药生物技术有限公司 一种替格瑞洛分散片及其制备方法
CN116370423A (zh) * 2023-02-28 2023-07-04 天津力生制药股份有限公司 一种替格瑞洛口腔崩解片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR017014A1 (es) 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
JPH11199517A (ja) * 1997-10-31 1999-07-27 Meiji Seika Kaisha Ltd 口腔内速崩壊性錠剤
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
WO2007018057A1 (ja) * 2005-08-05 2007-02-15 Freund Corporation 口腔内速崩壊錠およびその製造法
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
US20080045548A1 (en) * 2006-08-21 2008-02-21 Astrazeneca Ab Pharmaceutical Compositions
WO2011067571A1 (en) 2009-12-03 2011-06-09 Astrazeneca Ab Co - crystals of a triazolo [4,5 - d] pyrimidine platelet aggregation inhibitor
ES2550033T3 (es) * 2009-12-23 2015-11-04 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor

Also Published As

Publication number Publication date
CN104661649A (zh) 2015-05-27
MX2015003866A (es) 2015-07-17
EP2908802A1 (en) 2015-08-26
WO2014059955A1 (en) 2014-04-24
IL238036B (en) 2019-05-30
EA201590745A1 (ru) 2015-08-31
JP6301934B2 (ja) 2018-03-28
UA116784C2 (uk) 2018-05-10
CZ2012705A3 (cs) 2014-04-23
ZA201501954B (en) 2017-04-26
JP2015533129A (ja) 2015-11-19
HK1205456A1 (en) 2015-12-18
KR20150067153A (ko) 2015-06-17
IL238036A0 (en) 2015-05-31

Similar Documents

Publication Publication Date Title
BR112015008076A2 (pt) composição farmacêutica, e, método de preparar uma composição
BR112017010141A2 (pt) Forma cristalina de hidrogenossulfato de (s)-n-(5- ((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5- a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
CL2014003566A1 (es) Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson.
PE20150637A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
BR112012029653A2 (pt) formulação tópica para um inibidor jak
MX2016008363A (es) Combinaciones farmaceuticas.
CA2918938C (en) Substituted aminopyrimidine compounds and methods of use
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
MA38347A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
CL2007001166A1 (es) Compuestos derivados de pirimidina condensada, inhibidores de pi3-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicion farmaceutica
BR112015007586A2 (pt) derivados de pirrolo[3,2-d]pirimidina para o tratamento de infecções virais e outras doenças
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
ECSP10010695A (es) Compuestos de piridina
WO2012155066A3 (en) Spiro-oxindole mdm2 antagonists
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
BR112014012628B8 (pt) Dihidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp
EA201892150A1 (ru) Распадающиеся в полости рта таблетки
BR112014029708A2 (pt) composto de pirrolo[2,1-f][1,2,4]triazina, método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina e uso do composto de pirrolo[2,1-f][1,2,4]triazina
BR112016027674A2 (pt) Formas melhoradas de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas
BR112015012111A2 (pt) composição farmacêutica
BR112015021097A2 (pt) formulações de compostos orgânicos
EA024825B8 (ru) Сокристалл тикагрелора с 3-гидрокси-2-нафтойной кислотой, способ его получения и применение
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
MY175052A (en) Crystalline forms of (s) -4-amino-n- (1- (4 - chlorophenyl) - 3 - hydroxypropyl) -1- (7h - pyrrolo [2, 3-d] pyrimidi n-4-yl) piperidine-4-carboxamide
BR112016015175A2 (pt) Formulação farmacêutica, método para a fabricação de uma formulação farmacêutica compreendendo sildenafila e clomipramina e comprimido

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.